EAM
BMY icon

Eukles Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Eukles Asset Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,196
Closed -$80K – 208
2021
Q2 		$80K Buy
+1,196
New +$78K 0.04% 140

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Eukles Asset Management's BMY Position: Q3 2021 in Review

Eukles Asset Management sold out of Bristol-Myers Squibb (BMY) in Q3 2021, closing a stake of 1,196 shares — an estimated $80K sold.

Eukles Asset Management first reported a position in BMY in Q2 2021 and held it in 1 quarter. The position peaked at $80K in Q2 2021. 2,293 funds tracked by Wall St. Rank hold BMY as of Q3 2021.

  • Eukles Asset Management reported no remaining Bristol-Myers Squibb position as of Q3 2021 after selling out during the quarter.
  • Eukles Asset Management sold 1,196 Bristol-Myers Squibb shares in Q3 2021, an estimated $80K.
  • Eukles Asset Management first reported a position in Bristol-Myers Squibb in Q2 2021 and held it in 1 quarter.
  • Eukles Asset Management's Bristol-Myers Squibb position peaked at $80K in Q2 2021.
  • 2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2021.

Based on Eukles Asset Management's 13F filing for Q3 2021, filed 28 Oct 2021.